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Objectives. Rats with abdominal heterotopic heart trans- 
plants were studied to determine whether cardiac aliografl 
rejection could be assessed by immunoscintigraphy target- 
ing intercellular adhesion molecule-1 (ICAM-1), which was 
induced on aliografted organ cells in association with rejec- 
tion. 
Background. It is important to detect early rejection before 
development of myocyte necrosis. Although a variety of methods 
for the detection of cardiac rejection have been investigated, 
histologic inspection of biopsied samples is still used routinely for 
clinical diagnosis of rejection. 
Methods. DA rat (RT.I") hearts were transplanted into PVG 
rats (RT-lC). Immunohistologic examination of the allografts 
demonstrated that ICAM-1 induction on vascular endothelial 
cells was observed as early as 4 days after transplantation in this 
combination. Thirty-nine allografled rats and seven isografted 
rats were studied. One day after injection of 100 pCi of rain- 
labeled anti-ICAM-1 monoclonal antibody (1A29), planar images 
were obtained. 
Results. Rejecting ailografts showed increased radiotracer up- 
take and could be identified on the images as early as 5 days after 
transplantation. In contrast, nonrejecting cardiac allografls and 
isografts did not show specific uptake. Mildly rejecting allografts, 
with mononuclear cell infiltration but without significant myocyte 
necrosis, could be scintigraphically identified, and the level of 
radiotracer uptake reflected the histologic severity of rejection. 
Accumulation of rain-labeled monoclonal antibody of isotype- 
matched irrelevant specificity was not detected in the rejecting 
allografts. 
Conclusions. These data indicate that ICAM-I induction can be 
assessed quantitatively by radioimmunoscintigraphy. Radioim- 
munoscintigraphy is a sensitive method for early detection and 
assessment of cardiac allografl rejection. 
(J Am Coil Cardio11995;26:793-9) 
Heart transplantation is an accepted treatment for patients 
with life-threatening heart failure. Rejection of the trans- 
planted heart is a serious complication of this treatment. 
Detection of rejection requires histologic inspection of myo- 
cardial specimens obtained through endomyocardial biopsy 
(1). However, endomyocardial biopsy is invasive, costly, prone 
to sampling error and very dependent on the experience of the 
reader. To avoid these problems, noninvasive methods of 
detecting heart ransplant rejection are desirable. Noninvasive 
detection of early rejection before development of myocyte 
necrosis should be advantageous for monitoring of patients. 
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Scintigraphy targeting the immune reaction may provide an 
approach to solve this problem. This approach also may allow 
the assessment of pathophysiologic mechanisms of the rejec- 
tion process. 
We previously demonstrated (2-4) that rejecting cardiac 
and renal allografts can be detected by radioimmunoscintigra- 
phy targeting donor-specific and nonspecific MHC class II 
antigens in murine models. Although rejected organs are 
visualized by this technique, clinical utility of this approach as 
not been evaluated. 
Primary allograft transplant rejection of vascularized organs 
is mediated by T cells that attack endothelial nd parenchymal 
cells bearing foreign histocompatibility antigens (5). Adhesion 
of T cells to vascular endothelium is a necessary step for 
activation of T cells. Intercellular adhesion molecule-1 
(ICAM-1) is one of the adhesion molecules that activate T
cells and mediate the adherence of T cells to antigen- 
presenting cells (6-9). ICAM-1 normally is expressed on 
vascular endothelial cells, fibroblasts, epithelial cells, macro- 
phages and activated lymphocytes (10,11). It also is induced on 
allografted organ cells early in rejection (12-14). We previ- 
ously showed (15) that ICAM-1 plays a crucial pathophysio- 
logic role in rejection by working with lymphocyte function 
associated antigen-1 (LFA-1) (15). Therefore, the detection of 
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ICAM-1 induction may provide an early marker of immune 
activation in cardiac allograft transplantation. The present 
study was performed to determine whether radioimmune 
scintigraphy targeting ICAM-1 can be used to detect rejection 
of cardiac allografts. ICAM-I induction was assessed immuno- 
histologically and compared with induction of MHC class I and 
class II antigcns. 
Methods  
Animals. Inbred male rats (weight 150 to 200 g) of the 
PVG (RT-F) strain were used as recipients, and those of the 
DA (RT-I a) strain were used as donors. They were purchased 
from a commercial source (Bantin & Kingman). All animal 
experiments were carried out according to National Institutes 
of Health guidelines. 
Monocional antibodies. Hybridoma cells 1A29 (anti-rat 
ICAM-1, mouse lgGl) (16) were injected into nude mice to 
produce ascites. The antibody was purified by a protein G 
affinity column from ascitic fluids. Monoclonal antibody of 
irrelevant specificity (MOPC21. mouse IgG1; Sigma Corp.) 
was used as an isotype-matched control. WT. 1 (anti-rat LFA-1. 
mouse IgG2a) (17) and F17-23-2 (anti-rat major histocompat- 
ibility complex [MHC] class II polymorphic determinant, 
mouse lgG1) monoclonal antibodies also were purified from 
ascitic fluids. The MN4-91-6 (anti-rat MHC class I polymor- 
phic determinant, mouse lgGl) monoclonal antibody was 
purchased from Serotec. The FI7-23-2 and MN4-91-6 mono- 
clonal antibodies react with DA but not with PVG rats (18). 
Heart transplantation. Hetcrotopic rat heart transplanta- 
tion was performed according to a modification (4) of the 
method of Ono and Lindsey (19). Recipient and donor rats 
were anesthetized intraperitoneally with 50 mg/kg body weight 
pentobarbital sodium. Heterotopic heart transplantation was 
performed by anastomosing the donor aorta and pulmonary, 
artery to the recipient abdominal aorta and inferior vena cava, 
respectively. The strength of the graft heart beat was checked 
daily by palpation. 
Animal groups. Fifty-three DA hearts were transplanted 
into PVG recipients. Twenty-nine of them were randomly 
assigned for scintigraphy using ~In-labeled IA29 at 2 to 14 
days after transplantation. Ten of the 53 allografted rats were 
treated with FKS06 (1 mg:'kg per day for 7 days, intramuscular 
injection). Five allografted rats without treatment were in- 
jected with 11 lln.labeled MOPC21 as the control group. Nine 
allografted rats were used for immunohistologic study. Control 
scintigraphy also was performed by using ~ r In-labeled IA29 in 
seven isografted rats (DA to DA or PVG to PVG). 
Radioisotope labeling and seintigraphy. Labeling and scin- 
tigraphy were performed as described (2,4,20). Briefly, purified 
1A29 or MOPC21 was coupled to a bifunctional chelating 
agent, diethylenetriamine pentaacetic acid (DTPA), and the 
conjugate was labeled with indium-Ill chloride immediately 
before injection (21). One hundred microcuries of radiotracer 
was injected into the tail vein 24 h before scintigraphy. Planar 
images were obtained igitally on a dedicated computer system 
by using a gamma camera (Ohio-Nuclear Sigma 410) equipped 
with a parallel-hole medium energy collimator. The images 
were evaluated by two independent observers in a blinded 
manner .  
Biodistribution and histologic study. Rats were killed after 
scintigraphy. Tissue biodistribution f radioactivity was deter- 
mined as previously described (2,4,20). Graft, native heart, 
lung, liver, spleen, kidney and blood were collected and 
weighed. Radioactivity was counted by a gamma-well scintilla- 
tion counter. The grafts were fixed in 10% neutral buffered 
formalin for hematoxylin and eosin staining. The samples 
identified by code were graded according to the working 
formulation of the International Society for Heart Transplan- 
tation (1) by a cardiac pathologist in a blinded manner. 
Immunohistologic study. Allografted hearts at 2 to 14 days 
after operation and normal DA rat hearts were studied immu- 
nohistologically. Samples were embedded in OCT compound 
(Sigma Corp.) and kept frozen in liquid nitrogen. Cryostat 
sections of 4 /xm were prepared, air-dried on poly-L-lysine- 
coated slides and fixed in acetone for 8 min. After blocking 
with normal rabbit serum (1:100 dilution in phosphate- 
buffered saline) at room temperature for 20 rain, samples were 
incubated with mouse anti-rat IgG monoclonal antibodies 
(1A29, WT.1, F17-23-2 and MN4-91-6) at room temperature 
for 60 rain, washed in phosphate-buffered saline and incubated 
with fluorescein isothiocyanate-conjugated rat serum- 
adsorbed rabbit anti-mouse IgG monoclonal ntibody at room 
temperature for 30 rain. After washing in phosphate-buffered 
saline, they were photographed under a Nikon fluorescence 
microscope. 
Control samples were reacted without mouse antirat IgG 
monoclonal antibody incubation. Several samples were ob- 
tained from rats injected with ~lln-labeled 1A29 for scintigraphy. 
These samples were reacted in the same manner, skipping the 
incubation with a primary monoclonal ntibody (1A29). 
Statistical analysis. All data in the text and tables are 
expressed as mean value + SEM. Comparisons of data be- 
tween the two groups of Uqn-labeled antibody were per- 
formed by the Mann-Whitney U test. Differences between the 
values of myocardial radiotracer uptake within each graft 
subgroup and the ratios within the five histologic degrees of 
rejection were compared by one-way analysis of variance of the 
Kruskal-Wallis test and the Scheffe F test; p < 0.05 was 
considered statistically significant. Statistical testing was per- 
formed using commercial software (StatView Version 4.02). 
Resu l ts  
Function and histoiogic examination of cardiac aUografts. 
The intensity of the cardiac impulse declined gradually in 
parallel with the progression of graft rejection. Nontreated 
cardiac allografts topped beating between 15 and 20 days after 
transplantation. I  contrast, all cardiac isografts and FK506- 
treated allografts continued beating at the time of sacrifice. 
Histopathologic examination of the allografts ranged from 
normal to severe rejection. Focal lymphocyte infiltration was 
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Figure 1. Time course of Hlln-labeled 1A29 uptake in the grafts. The 
ratio of myocardial radiotracer uptake in the graft o that in the native 
heart increases progressively with time in the allografted rats without 
FKS06 treatment (solid circles). In contrast, isografted rats (open 
circles) and allografted rats with FK506 treatment ( riangles) did not 
show a significant increase in ratio throughout the course of observa- 
tion. ICAM-1 = intercellular dhesion molecule-l; mAb = monoclo- 
nal antibody. 
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Figure 2. Comparisons ofgraft/native h art iJ ~In-labeled 1A29 uptake 
versus histologic severity of rejection. Radiotracer uptake in allografts 
with grades 1A, 1B, 3B and 4 rejection is significantly greater than 
that in rats with nonrejecting grafts. Symbols and abbreviations a in 
Figure 1. 
observed from 4 days after transplantation. Myocyte necrosis 
developed at -6  to 8 days and progressed with time. At 12 to 
14 days, myocyte necrosis with edema, hemorrhage and vascu- 
litis was obvious. 
Uptake of rain-labeled 1A29. Uptake of llqn-labeled anti -
ICAM-1 monoclonal ntibody (1A29) in the allografted hearts 
without reatment (0.61 + 0.05% injected ose/organ,  = 29, 
p < 0.001) was greater than that in the isografted rats (0.17 _+ 
0.02% injected dose/organ,  = 7) or that in the allografted 
rats treated with FK506 (0.14 +_ 0.01% injected dose/organ, 
n = 10). 
The ratio of myocardial 111In-labeled 1A29 uptake in the 
graft versus that in the native heart increased from day 5 of 
transplantation a d accelerated with time after transplantation 
in the nontreated allografts (Fig. 1). The ratio of myocardial 
l~ lin.labeled 1A29 uptake in the graft versus that in the native 
heart in the nontreated allografts (n = 29) ranged from 1.31 to 
8.58. In contrast, the isografted rats (n = 7) did not show a 
significant increase in ratio (0.70 to 1.90) as late as 12 days 
after transplantation. The allografted rats treated with FK506 
(n = 10) also did not show a significant increase in ratio (0.61 
to 1.31) as late as 22 days after transplantation. 
The level of the ratio reflected the histologic severity of 
rejection (Fig. 2). The ratio was 1.14 + 0.10 for normal grafts 
(n -- 21), 3.79 ± 0.50 for grafts with grade 1A rejection (n = 
11, p < 0.001 vs. normal), 5.53 ± 0.63 for grafts with grade 1B 
rejection (n = 8, p < 0.001 vs. normal), 5.70 _+ 0.46 for grafts 
with grade 3B rejection (n = 4, p < 0.001 vs. normal) and 
5.91 _+ 0.44 for grafts with grade 4 rejection (n = 2, p < 0.001 
vs. normal). 
Uptake of nlln-labeled MOPC21. Five allografted rats 
without reatment were imaged with t llln-labeled monoclonal 
antibody of irrelevant specificity (MOPC21) as a control group. 
Indium-Ill-labeled MOPC21 did not accumulate in mildly 
rejecting allografts (0.21 ± 0.03% injected dose/organ for 1A 
[n = 3] and 1B rejection [n = 2]) compared with 11 aln.labeled 
1A29 uptake of rejected allografts with similar severity (0.60 _+ 
0.07% for 1A [n = 11] and 1B rejection [n = 8], p < 0.01). 
Scintigraphic detection of cardiac rejection. Visualization 
of the rejecting allografts on the scintigraphic images preceded 
the decline in graft beating. The rejecting allografts howed 
increased t llin_labeled 1A29 uptake and were scintigraphically 
identified as early as 5 days after transplantation (Fig. 3). 
Rejecting allografts with focal lymphocyte infiltration but 
without myocyte necrosis (grade 1A) could be clearly visual- 
ized (Fig. 3, B and C). Eight of the 11 allografts with grade 1A 
rejection could be identified. All 14 cardiac allografts with mild 
(grade 1B), moderate (grade 3B) and severe (grade 4) rejec- 
tion showed intense and unequivocal accumulation of radio- 
tracer (Fig. 3, D and E). In contrast, the nonrejecting cardiac 
allografts (Fig. 3A), including those in the FK506-treated rats 
(Fig. 3F) and isografted rats (Fig. 3G) did not show specific 
radiotracer uptake and could not be identified on the image. 
Rejecting allografts were not visualized by 111In-labeled 
MOPC21 (Fig. 3H). 
Cardiac allograft rejection was detected by scintigraphy 
with 88% sensitivity (22 of 25 true positive results) and 100% 
specificity (21 of 21 true negative results). There were no false 
positive or false negative results for rejection grades 1B, 3B or 
4. The threshold percent injected dose/organ value for a 
positive image was 0.40. This value was sufficiently greater than 
that for nonrejected allografts (0.32 + 0.02) or isografts 
(0.17 + 0.02). Percent injected dose/organ was >0.40 in 7 of 
the 11 allografts with grade 1A rejection or all of the 14 
allografts with grade 1B, 3B or 4 rejection. Percent injected 
dose/organ of two allografts with grade 1A rejection was 
<0.40. These grafts were not visualized. Percent injected 
dose/organ of the remaining two allografts with grade 1A 
rejection was 0.40: One graft was visualized, and the other was 
not. 
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Table 1. Biodistribution f H l in_Labeled 1A29 and rain-Labeled 
MOPC21 in Various Organs (mean _+ SEM) 
FK5(~ 
Treatment 
mAb IA29 (% ID/g) mAb MOPC21 
Allografted (% ID/g): 
Nongrafted Rats Nongrafted 
Rats, Rats, 
n=l l  n=29" n=10t n=7 
Body. weight (g) 227 : 5 190 : 5 202 +_ 6 200 _+ 21 
Grafted heart -- 1.00 + 0.06 0.34 _+ 0.02 -- 
Native heart 0.25 _+ 0.01 0.32 _+ 0.01 0.33 -+ 0.01 0.24 + 0.30 
Lung 5.71 + (I.21 6.22 +_ 0.~ 5.97 _+ 0.30 0.68 +_ 0.07 
Liver 5.18 _+ 0.28 5.91 + 0.16 5.35 _+ 0.31 1.57 _+ 0.21 
Spleen 4.'40 _+ 0.22 5.47 _+ 0.29 4.47 + 0.27 2.15 _+ 0.23 
Kidney 2.77 +_ 0.12 3.~ _+ 0.09 3.28 _+ 0.08 3.29 _+ 0.43 
Blood 0.33 _+ 0.02 0.30 _+ 0.01 0.33 + 0.0l 0.65 _+ 0.13 
*Without. ?with FK506 treatment. MAb = monoclonal antibody. 
Figure 3. Representative scintigrams after injection of IHIn-labclcd 
1A29 (anti-ICAM-1 monoclonal antibody) in rats with a heterotopic 
heart transplant. A nonrejected allograft 4 days after transplantation 
(grade 0 rejection) is not imaged (A). Rejecting allografts at day 5 (Bt 
(grade 1A), day 6 (C) (grade 1A), day 6 (D) (grade 3B) and day 8 {El 
(grade 3B) are clearly visualized in the scintigrams (arrows). A 
nonrejected allograft with FK506 treatment (F) and an isograft (G) are 
not visualized, rain-labeled MOPC2I (isotype-matched control mono- 
clonal antibody with irrelevant specificity) does not accumulate in a 
rejecting allograft at day 8 (H) (grade IA). Li = liver: Lu : lung. 
Biodistribution of l llln.labeled anti-lCAM-1 monoclonal 
antibody. The results of radiotracer accumulation i the graft, 
recipient native heart, lung, liver, spleen, kidney and blood arc 
shown in the Table 1. The 111In-labeled 1A29 uptake was 
significantly greater than ~11in_labeled MOPC21 uptake in the 
lung, liver and spleen. No specific uptake of it iin.labeled 1A29 
or 111in_labeled MOPC21 was found in the native heart. 
Expression of ICAM-1, LFA-1 and MHC antigens in car- 
diac grafts and normal hearts. Results of scmiquantitative 
analysis of 1CAM-1 and MHC class I and class II antigen 
expression are presented in Table 2. ICAM-1 expression was 
observed on normal capillary, endothelial cells but not on 
cardiac myocytes. Enhanced expression of ICAM-1 in cardiac 
allografts was observed on capillary, endothelium from day 4 
after transplantation before the advent of myocyte necrosis 
(Fig. 4A). This expression correlated with scintigraphic visual- 
ization of rejecting allografts by 111in_labeled 1A29. Six to 8 
days after transplantation, expression of ICAM-1 extended to 
the sarcolemma nd was seen as late as 14 days (Fig. 4B). 
Allografts injected with IA29 in vivo immediately before 
excision for scintigraphy showed the same pattern as those 
described previously. Infiltration of LFA-1 expressing cells was 
found from day 4 or 5. 
Expression of MHC class II antigen in normal rat hearts 
and nonrejecting cardiac allografts was confined to interstitial 
dendritic cells. Induction of MHC class II antigen was ob- 
served on the capillary endothelium from day 4 after trans- 
plantation in parallel with the induction of ICAM-1 (Fig. 4C). 
The expression extended to the surface of myocytes and to the 
endothelium of small arteries on days 6 to 8 after transplan- 
tation (Fig. 4D). The expression of MHC class II antigen on 
myocytes declined with time. The distribution of MHC class I 
antigen in the normal rat heart was observed in the endothe- 
lium of small arteries and interstitial dendritic ells. Strong and 
diffuse expression was found on myocytes from days 6 to 8 and 
continued throughout the course of the study. 
Discuss ion  
Characteristics of ICAM-1 induction. ICAM-1 mediates T
cell adhesion to antigen-presenting cells and activates T cells 
working with its counterreceptor LFA-1 (7,8,22-24). It has 
been reported (12-14,25-29) that ICAM-1 is induced from the 
early stage of rejection in allografted liver, kidney and heart. 
Taylor et al. (26) demonstrated that an expression of adhesion 
molecules (ICAM-1, vascular cell adhesion molecule-1 
[VCAM-1] and E-selectin), MHC class I and DR antigen on 
capillary endothelium increased during acute rejection. 
ICAM-1 also was induced on the myocardial membrane and 
intercalating disk. E-selectin and VCAM-1 represent early 
predictive markers of acute cardiac rejection, and ICAM-1 
could be an important cofactor in both specific immune 
recognition and cellular recruitment (26,27). Yanio et al. (28) 
showed a strong correlation between ICAM-1 expression and 
the histologic severity of cardiac rejection in 25 heart trans- 
JACC Vol. 26, No. 3 OHTANI ET AL. 797 
September 1995:793-9 ICAM-1 SCINTIGRAPHY FOR CARDIAC REJECTION 
Table 2. Expression of ICAM-I and MHC class I and II Antigens in Cardiac Allografts 
Myocytes Capillary Endothelium 
MHC Class I MHC Class lI ICAM-1 MHC Class I MHC Class II ICAM-1 
Before transplantation +_ - - + - -+ 
After transplantation 
2-3 d -+ - + + -+ 
4-5 d + = -+ + + + 
6-8d + + + + + + 
9-14 d + + + + + - 
d = days; ICAM-1 = intercellular dhesion molecule-l; MHC = major histocompatibility complex; - = no expression; + = faint expression on a few vessels or 
myocytes; + = strong expression on most vessels or myocytes. 
plant recipients. We previously demonstrated (15,30) that 
short-term administration of monoclonal antibodies to 
ICAM-1 and LFA-1 allows induction of immunologic toler- 
ance to cardiac allografts in mice. LFA-1 produces co- 
stimulatory signals that are required for optimal T-cell activa- 
tion on binding with its ligand ICAM-1 (8). Therefore, 
induction of ICAM-1 should be one of the initial and essential 
events in the pathogenesis of rejection. The detection of 
ICAM-1 induction, therefore, could provide an early and 
specific marker of immune activation associated with acute 
rejection. 
Immunohistochemical comparison of ICAM-1 and MHC 
class II induction. Immunohistologic studies from other lab- 
oratories (10,11,31) revealed that ICAM-1 is normally ex- 
pressed on vascular endothelial cells, fibroblasts, epithelial 
cells, macrophages and activated lymphocytes. Although low 
levels of MHC class I antigen are expressed on normal cardiac 
myocytes, class II antigen is not detected (32). Induction of 
donor-type class I and II antigens (18,33,34) and ICAM-1 
(26-29) in rejecting cardiac allografts has been reported. 
Results of our immunohistologic studies generally confirmed 
these previous observations. Enhanced expression of ICAM-1 
as well as MHC class II antigen on the capillary endothelium 
was observed from day 4 after transplantation in parallel with 
the development of mononuclear cell infiltration. The time 
course of induction of donor-type class II antigen and ICAM-1 
was similar. 
Scintigraphic detection. The level of radioactive anti- 
ICAM-I monoclonal antibody uptake reflected the histopatho- 
logic severity of rejection. Rejecting allografts with no significant 
myocyte necrosis could be clearly identified by the scintigrams. 
There were no false positive images in the grafts without rejec- 
tion. Because 111In-labeled monoclonal antibody of irrelevant 
specificity did not accumulate in the rejecting allografts, it is 
unlikely that rain-labeled anti-ICAM-1 monoclonal antibody 
nonspecifically accumulated in sites of rejection. 
Figure 4. Immunohistochemical study for ICAM-1 
and MHC class II antigens in allografted hearts. An 
allograft 4 days after transplantation (rejection grades 
1A [A and C]) and another allograft 10 days after 
transplantation (grade 3B [B and D]) are reacted with 
anti-ICAM-1 monoclonal antibody (A and B) and 
anti-MHC class II antigen monoclonal antibody (C 
and D). At day 4, focal expression of ICAM-1 (A) and 
MHC class II antigen (C) on the capillary endothelium 
as well as interstitial cells is demonstrated. An allografl 
with advanced rejection at day 10 shows trong expres- 
sion of both ICAM-1 and MHC class II antigen on the 
sarcolemma of myocytes. 
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Grades 2 and 3A are the most common rejection types een 
clinically. The rats in our study did not develop these two 
rejection grades, probably due to the difference between the 
two species in the progression of the rejection process, and to 
the modulation by immunosuppressive tr atment. 
Grade 1B rejection could not be distinguished from grades 
3B or 4 rejection by radioimmunoscintigraphy. Using this 
technique patients with 1B rejection might be overtreated, 
because 1B rejections are not usually treated clinically. Scin- 
tigraphy may be too sensitive in this respect. However, reliable 
noninvasive clinical tests for detecting early rejection should be 
beneficial. The frequency of endomyocardial biopsy could be 
reduced by radioimmunoscintigraphy. In the present study, 
there were no false negative results for rejection grades 1B, 3B 
or 4. Also, we previously reported (20) that ~Jqn-labeled 
antimyosin scintigraphy is a reliable technique for detecting 
grade 3B rejection. The combination of two noninvasive 
techniques by using two different isotopes might allow identi- 
fication of early rejection with cellular infiltrates but without 
myocyte necrosis. Further experiments are required to test this 
possibility. 
Effects of FK506. Rats treated with FK506 did not develop 
acute rejection, and l~lin_labeled anti-ICAM-1 monoclonal 
antibody did not accumulate in the grafts. Expression of 
ICAM-1 in the allografts treated with FK506 could not be 
distinguished from that of normal heart. FK506 has been 
shown to inhibit production of T cell-derived lymphokines, 
such as interleukin-2 and interferon-,/(35). FK506 is supposed 
to suppress induction of ICAM-1 and MHC class II antigen 
because induction of these molecules is certainly a conse- 
quence of local production of lymphokines released from 
infiltrating leukocytes (9,31,36). Therefore, it is reasonable that 
lalln-labeled anti-ICAM-1 monoclonal antibody uptake in 
FK506-treated allografts did not increase relative to that in 
isografts, reflecting the absence of active rejection. 
Reason for high background. Higher accumulation of 
rain-labeled anti-ICAM-1 monoclonal antibody was observed 
in the lungs and liver in normal rats as well as in those with 
rejecting cardiac allografts. Although the nature of this accu- 
mulation is a matter for further investigation, normal expres- 
sion of ICAM-1 in pulmonary alveolar cells and vascular 
endothelium ay account for it. Normal sinusoidal cells in 
liver have also been shown (37) to express ignificant amounts 
of ICAM-1. Indium-11 l-labeled monoclonal antibody of irrel- 
evant specificity did not accumulate in the normal liver and 
lungs, suggesting that the increased lung and liver uptake were 
due to specific antigen recognition. 
High background might cause difficulties when radioimmu- 
noscintigraphy is applied to orthotopic heart transplantation. 
Use of single-photon emission computed tomography would 
be helpful for improvement of spatial dissolution. It is also 
possible to perform serial scintigraphy in individual patients. 
Comparisons of serial scintigraphic images would be useful for 
determining changes in radiotracer uptake in the cardiac graft. 
These possibilities hould be further evaluated in orthotopic 
heart transplantation models. 
Comparison of radioimmune scintigraphy targeting MHC 
class II and ICAM-1 and other noninvasive methods. We 
previously reported that radioimmune scintigraphy targeting 
MHC class II antigen allows detection of early rejection of 
cardiac (2,4) or renal allografts (3). In our previous investiga- 
tion (4) we used 123I-labeled monoclonal antibodies against 
monomorphic or polymorphic determinants of MHC class II 
antigen in the same donor-recipient combination. Although 
the use of antipolymorphic portion monoclonal antibody of- 
fered better images, from a practical point of view the need for 
donor-specific monoclonal antibodies would limit the utility of 
the scintigraphy as applied to clinical cases. In contrast, 
anti-ICAM-1 monoclonal antibody can be applied to imaging 
of rejection irrespective of donor haplotype. Anti-MHC class 
II scintigraphy using the antimonomorphic portion monoclo- 
nal antibody was also performed using the same protocol as the 
present study. The ratio of myocardial radiotracer uptake in 
the graft to that in native heart for grade 1A rejection 
determined by this technique was 1.41 and 1.54, and that for 
grade IB rejection 1.64 and 3.75. In the present study, how- 
ever, the ratios for 1A and 1B rejection were 5.53 -+ 0.63 (n = 
11, between 1.51 and 6.75) and 5.70 +- 0.46 (n = 8, between 
3.61 and 8.58), respectively. Anti-ICAM-1 imaging therefore 
appears to be more sensitive than anti-MHC class II imaging. 
A variety of noninvasive methods for detection and quan- 
tification of heart transplant rejection have been investigated. 
Indium-ill-labeled lymphocyte (38,39) has been used for 
imaging. However, correlation between severity of rejection 
and amount of radioactivity of this imaging agent has not been 
shown. Ferran et al. (27) suggested that few activated T cells 
expressing the interleukin-2 receptor are seen in intense 
infiltrates, but the expression is not predictive of rejection. 
Scintigraphy with rain-labeled antimyosin is reported to be 
useful in detecting moderate and severe cardiac rejection 
(20,40,41). However, because myocyte necrosis associated with 
rejection is essential for imaging of antimyosin, this method is 
not sensitive nough to detect early heart transplant rejection 
without myocyte necrosis and not specific for immune activa- 
tion. 
Implications. The physiologic roles of ICAM-1 induction are 
still a matter of investigation. It has been reported that ICAM-1 
is induced not only in rejecting organs, but also in tissues 
undergoing autoimmune injury (42) and inflammation (43) and in 
malignant umors (44). ICAM-1 also has been shown to be a 
receptor of rhinovirus (45). The noninvasive detection of ICAM-1 
induction presented inthe present study could allow investigation 
of the pathophysiologic roles of the induction phenomenon i
organ rejection and other immunologic disorders. Radioimmu- 
noscintigraphy is potentially applicable to the detection and 
localization of these disorders as well. 
Conclusions. We demonstrated that the induced ICAM-1 
resulting from rejection can be visualized in vivo by radioim- 
munoscintigraphy, a noninvasive method can detect early 
rejection and allows its quantitative assessment. Radioimmu- 
noscintigraphy could be potentially useful for detection of 
cardiac allograft rejection in patients and would facilitate the 
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study of the mechanisms of interaction of ICAM-1/LFA-1 in 
various immunologic disorders. Further studies are needed to 
determine its clinical utility, 
We thank Dr. Yukio Maruyama for stimulating discussions and review of the 
manuscript. 
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